Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis
ConditionAllergic Rhinitis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorZheng Liu
About this trial
The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.), which are still limited. Arbidol may inhibit molecular targets involved in the pathogenesis of AR. This study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.
Eligibility criteria
Qualifiers
1. Patients with allergic rhinitis (in line with the diagnostic criteria of the "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2015, Tianjin)" formulated by the Rhinology Group of the Otolaryngology-Head and Neck Surgery Branch of the Chinese Medical Association).
2. At least 2 nasal symptoms are moderate or above (referring to sneezing, runny nose, nasal itching, nasal congestion with at least 2 symptoms ≥2 points).
3. Female subjects are not pregnant or lactating and have no pregnancy and lactation plans during the trial medication period.
4. The subject has not participated in other clinical trials in the previous three months and agrees not to participate in other clinical trials before reaching the endpoint of this trial.
Disqualifiers
1. Who are allergic to Arbidol.
2. Patients with abnormal liver and kidney function (ALT and AST exceed the maximum limit of normal value by 1.5 times, and Cr exceeds the upper limit of normal value).
3. Patients with abnormal ECG parameters and clinically significant (PR>220ms, QRS>120ms, QTc>450ms) and bradycardia.
4. Patients with severe asthma or acute asthma exacerbations.
Trial design
Treatments tested in this trial
- Arbidol
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Zheng Liu
Lead sponsor
Huazhong University of Science and Technology
Sponsor institution
National Natural Science Foundation of China
Collaborator
Source ClinicalTrials.gov